



**QUEEN'S
UNIVERSITY
BELFAST**

The use of high-throughput sequencing to investigate an outbreak of glycopeptide-resistant *Enterococcus faecium* with a novel quinupristin-dalfopristin resistance mechanism.

Shaw, T., Fairley, D. J., Schneiders, T., Pathiraja, M., Hill, R. L. R., Werner, G., Elborn, J., & McMullan, R. (2018). The use of high-throughput sequencing to investigate an outbreak of glycopeptide-resistant *Enterococcus faecium* with a novel quinupristin-dalfopristin resistance mechanism. *European Journal of Clinical Microbiology and Infectious Diseases*, 1-9. Advance online publication. <https://doi.org/10.1007/s10096-018-3214-x>

Published in:

European Journal of Clinical Microbiology and Infectious Diseases

Document Version:

Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:

[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights

Copyright 2018 the authors.

This is an open access article published under a Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Open Access

This research has been made openly available by Queen's academics and its Open Research team. We would love to hear how access to this research benefits you. – Share your feedback with us: <http://go.qub.ac.uk/oa-feedback>



The use of high-throughput sequencing to investigate an outbreak of glycopeptide-resistant *Enterococcus faecium* with a novel quinupristin-dalfopristin resistance mechanism

Timothy D. Shaw^{1,2} · D. J. Fairley^{1,2} · T. Schneiders³ · M. Pathiraja² · R. L. R. Hill⁴ · G. Werner⁵ · J. S. Elborn^{1,6} · R. McMullan^{1,2}

Received: 10 January 2018 / Accepted: 13 February 2018
© The Author(s) 2018. This article is an open access publication

Abstract

High-throughput sequencing (HTS) has successfully identified novel resistance genes in enterococci and determined clonal relatedness in outbreak analysis. We report the use of HTS to investigate two concurrent outbreaks of glycopeptide-resistant *Enterococcus faecium* (GRE) with an uncharacterised resistance mechanism to quinupristin-dalfopristin (QD). Seven QD-resistant and five QD-susceptible GRE isolates from a two-centre outbreak were studied. HTS was performed to identify genes or predicted proteins that were associated with the QD-resistant phenotype. MLST and SNP typing on HTS data was used to determine clonal relatedness. Comparative genomic analysis confirmed this GRE outbreak involved two distinct clones (ST80 and ST192). HTS confirmed the absence of known QD resistance genes, suggesting a novel mechanism was conferring resistance. Genomic analysis identified two significant genetic determinants with explanatory power for the high level of QD resistance in the ST80 QD-resistant clone: an additional 56aa leader sequence at the N-terminus of the *IsaE* gene and a transposon containing seven genes encoding proteins with possible drug or drug-target modification activities. However, HTS was unable to conclusively determine the QD resistance mechanism and did not reveal any genetic basis for QD resistance in the ST192 clone. This study highlights the usefulness of HTS in deciphering the degree of relatedness in two concurrent GRE outbreaks. Although HTS was able to reveal some genetic candidates for uncharacterised QD resistance, this study demonstrates the limitations of HTS as a tool for identifying putative determinants of resistance to QD.

Keywords Quinupristin-dalfopristin · *Enterococcus faecium* · Enterococcal resistance · High-throughput sequencing · Outbreak

Introduction

Enterococci are Gram-positive, facultatively anaerobic cocci that naturally colonise the human gastrointestinal tract and commonly cause nosocomial infections [1]. In February 2017, the World Health Organization named *E. faecium* in a priority list of pathogens to guide their strategy for tackling antimicrobial resistance [2].

Quinupristin-dalfopristin (QD) is a semi-synthetic 70:30 mixture of streptogramins A and B licenced for treatment of glycopeptide-resistant *Enterococcus faecium* (GRE) and methicillin-resistant *Staphylococcus aureus* (MRSA) infection [3]. Quinupristin and dalfopristin act synergistically to inhibit the ribosomal peptide elongation cycle with bactericidal effect.

QD resistance in *E. faecium* is uncommon but several of its genetic determinants have been well-described [4, 5]. In most cases, high-level QD resistance (MIC ≥ 4 $\mu\text{g/ml}$) is conferred

✉ Timothy D. Shaw
t.shaw@qub.ac.uk

¹ Centre for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK

² Department of Medical Microbiology, Kelvin Laboratory, Royal Victoria Hospital, Belfast, Northern Ireland, UK

³ Division of Infection and Pathway Medicine, University of Edinburgh Medical School, Edinburgh, Scotland, UK

⁴ Antimicrobial Resistance & Healthcare-Associated Infection, Public Health England, London, UK

⁵ National Reference Centre for Staphylococci and Enterococci, Robert Koch-Institute, Wernigerode Branch, Berlin, Germany

⁶ National Heart and Lung Institute, Imperial College London, London, UK

by enzymatic drug acetylation (encoded by the *vat* genes, particularly *vatD* and *vatE*) or drug efflux (encoded by *vgaA*, *vgaB* and *vgaD*) of quinupristin. The *vat* and *vga* families of genes are characteristically plasmid-borne and have been described in other Gram-positive organisms, mainly staphylococci [5]. Targeting of dalbapristin by resistance gene products may also be associated with low-level QD resistance (MIC < 4 µg/ml), with described mechanisms including drug degradation (*vgbA* and *vgbB*), efflux (*msrC*) and methylation of the 23S rRNA target site (*ermB*).

The discovery of novel genes and allele variants within the already-described families of QD resistance genes has led to speculation that there remain undiscovered genetic determinants of resistance [6, 7]. High-throughput sequencing (HTS) of enterococci has successfully identified undescribed genes of resistance, including those targeting linezolid, daptomycin and tigecycline [8–10]. HTS has also been useful in elucidating complex transmission routes in nosocomial outbreaks of GRE [11].

Two concurrent single-ward outbreaks of GRE were reported in Belfast in 2012. The two wards (ward A, a Haematology Unit, and ward B, a Critical Care Unit) were situated around 1 km apart within the same Hospital Trust. There is frequent movement of healthcare workers and patients between the two sites and between the two units. In response to the initial cases, GRE screening of new admissions to ward A and ward B was instigated until resolution of the outbreak.

GRE isolates from the outbreak were characterised by displaying low- or high-level resistance to QD. Genetic testing at the Public Health England Antimicrobial Resistance & Healthcare-Associated Infection (ARHAI) Reference Unit indicated the absence of *vatD* and *vatE* genes in the high-level QD-resistant GRE isolates. The impression from epidemiological and antibiogram analysis was that these isolates represented a Trust-wide outbreak. We hypothesised that a novel genetic mechanism was conferring high-level QD resistance in these isolates of GRE and sought to detect this mechanism using HTS. We also postulated that HTS could determine whether the two outbreaks were epidemiologically linked.

Materials and methods

Isolation

Enterococcal isolates were cultured from faeces of patients from two wards (ward A and ward B) in Belfast hospitals in the course of screening for carriage of GRE in an outbreak setting. The minimum inhibitory concentration (MIC, µg/ml) of QD was initially determined using an automated method (VITEK-2®, bioMérieux) in the local laboratory and confirmed using agar dilution (BSAC method) at the Public Health England reference laboratory. The QD MIC breakpoint

for resistance was defined as ≥ 4 µg/mL. Seven QD-resistant isolates of *E. faecium* that were representative of both wards over a 6-month period were selected for study. Five QD-susceptible isolates of GRE, including one sporadic GRE isolate from a Hospital Trust outside Belfast (ward C), cultured during the same screening exercise, were used as control strains.

QD-susceptibility testing

All *E. faecium* isolates that were QD-resistant or QD-susceptible by the agar dilution (BSAC method) at Public Health England were re-tested for QD-susceptibility using VITEK-2® (bioMérieux) in the local laboratory to confirm the persistence of phenotypic resistance prior to DNA extraction for HTS.

PCR detection of genes of interest

The presence of genes conferring resistance to QD (*vatA*, *vatB*, *vatC*, *vatD*, *vatE*, *vatH*, *vgaA*, *vgaB*, *vgaD*, *vgbA*, *vgbB*, *msrC* and *ermB*) in the 12 isolates was assessed by PCR amplification using primers and PCR conditions as previously published (Table 1) [6, 12, 13]. Genomic DNA was extracted using the PureLink® Genomic DNA Purification Kit (Invitrogen). The positive control organisms for PCR were *S. aureus* ES1767, *S. aureus* ES1768, *E. faecium* UW1965 and *E. faecium* UW3540. Sterile water was used as a negative control.

High-throughput sequencing

Sequencing libraries were prepared using the Nextera® DNA Library Prep Kit (Illumina) according to the manufacturer's instructions. The target insert size for libraries was 500 bp. Libraries were sequenced using the HiSeq 2000 sequencing system (Illumina, San Diego, CA) using 90 bp paired-end sequencing mode at the Beijing Genome Institute. Sequence data quality was assessed using FastQC software (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc>). All sequences were reported to be high quality, with median Phred quality scores above 30 across all bases for all samples.

De novo assembly

For each sample, paired-end de novo assembly was undertaken using *clc_assembler* software (<http://www.clebio.com/products/clc-assembly-cell>) with differing parameters. Limiting the output to contigs of 200 or more bases, 7 different insert size ranges were specified: 120–500; 170–500; 220–500; 270–500; 320–500; 370–500 and 420–500. The optimal assembly for each sample was defined as the

Table 1 Primers and conditions for the detection of known QD resistance genes by PCR

Gene	Primers	Sequence	GenBank accession no.	Size of product (bp)	PCR conditions
VatA	Vat-1 Vat-2	TGGAGTGTGACAAGATAGGC GTGACAACAGCTTCTGCAGC	L07778	512	Initial denaturing reaction at 94 °C for 3 min; 35 cycles at 94 °C for 1 min, 55 °C for 1 min and 72 °C for 1 min; final extension reaction at 72 °C for 10 min
VatB	vatB-1 vatB-2	GGCCCTGATCCAAATAGCAT GTGCTGACCAATCCCACCAT	U19459	558	Initial denaturing reaction at 94 °C for 3 min; 35 cycles at 94 °C for 1 min, 55 °C for 1 min and 72 °C for 1 min; final extension reaction at 72 °C for 10 min
VatC	vatC-O vatC-P	ATGAATTCGCAAAATCAGCAAGG TCGCTCGAGCTCTAGGTCC	AF015628	579	Initial denaturing reaction at 95 °C for 3 min and 60 °C for 2 min; 30 cycles at 72 °C for 20 s, 95 °C for 20 s and 60 °C for 20 s; final extension reaction at 72 °C for 1 min
VatD	satA-1 satA-2	GCTCAATAGGACCAGGTGTA TCCAGCTAACATGTATGGCG	L12033	271	Initial denaturing reaction at 94 °C for 3 min; 35 cycles at 94 °C for 1 min, 55 °C for 1 min and 72 °C for 1 min; final extension reaction at 72 °C for 10 min
VatE	satG-1 satG-2	ACTATACCTGACGCAAATGC GGTTCAAATCTTGGTCCG	AF139725	511	Initial denaturing reaction at 94 °C for 3 min; 30 cycles at 94 °C for 20 s, 52 °C for 40 s and 72 °C for 50 s; final extension reaction at 72 °C for 6 min
vgaA	vga-1 vga-2	AGTGGTGGTGAAGTAACACG CTTGCTCCTCCGCGAATAC	M90056	659	Initial denaturing reaction at 94 °C for 3 min; 35 cycles at 94 °C for 1 min, 55 °C for 1 min and 72 °C for 1 min; final extension reaction at 72 °C for 10 min
vgaB	vgaB-1 vgaB-2	TGACAATATGAGTGGTGGTG GCGACCATGAAATTGCTCTC	U82085	576	Initial denaturing reaction at 94 °C for 3 min; 35 cycles at 94 °C for 1 min, 52 °C for 1 min and 72 °C for 1 min; final extension reaction at 72 °C for 10 min
vgbA	vgb-1 vgb-2	TACAGAGTACCCACTACCGA TCAATTCCTGCTCCAGCAGT	M36022	569	Initial denaturing reaction at 94 °C for 3 min; 35 cycles at 94 °C for 1 min, 52 °C for 1 min and 72 °C for 1 min; final extension reaction at 72 °C for 10 min
vgbB	vgbB-Q vgbB-R	CAGCAGTCTAGATCAGAGTGG CATACGGATCCATCTTTTCC	AF015628	728	Initial denaturing reaction at 95 °C for 3 min and 60 °C for 2 min; 30 cycles at 72 °C for 20 s, 95 °C for 20 s and 60 °C for 20 s; final extension reaction at 72 °C for 1 min
ermB1	ermB-1 ermB-2	CATTTAACGACGAAACTGGC GGAACATCTGTGGTATGGCG	M11180	424	Initial denaturing reaction at 94 °C for 3 min; 25 cycles at 94 °C for 1 min, 52 °C for 1 min and 72 °C for 1 min; final extension reaction at 72 °C for 10 min
vatH	vatG1 vatG2	GTGGGAAAAGCATAACCT TTGCAGGATTACCACCAAC	GQ205627	200	Initial denaturing reaction at 94 °C for 5 min; 30 cycles at 94 °C for 30 s, 55 °C for 30 s, and 72 °C for 30 s; final extension reaction at 72 °C for 10 min
vgaD	vgaD1 vgaD2	CAACTGGAGCGAGCTGTTA GACAGCCGGATAATCTTTTG	GQ205627	201	Initial denaturing reaction at 94 °C for 5 min; 30 cycles at 94 °C for 30 s, 55 °C for 30 s, and 72 °C for 30 s; final extension reaction at 72 °C for 10 min
msrC	msrC3 msrC4	AAGGAATCCTTCTCTCTCCG GTAAACAAAATCGTTCCCG	AJ243209	343	Initial denaturing reaction at 95 °C for 3 min; 35 cycles 93 °C for 30 s, and 55 °C for 2 min at 72 °C for 90 s; final extension reaction at 72 °C for 10 min

assembly containing the largest contig. These optimal assemblies were selected for further analysis.

The *Enterococcus faecium* DO genome was used as a reference for contig ordering and for comparison to the study

strains. This strain is susceptible to QD ($MIC \leq 1 \mu\text{g/mL}$). The DO genome comprises a chromosome (NC_017960, 2,698,137 bp) and three plasmids (NC_017961, plasmid 1, 36,262 bp; NC_017962, plasmid 2, 66,247 bp and NC_017963, plasmid 3, 251,926 bp). For each sample, contigs were ordered using BLASTN comparison to the DO genome. Contig order relative to the DO genome was used to generate a reordered assembly for each sample. Contigs that did not align to the DO reference were placed first in the reordered assembly. Gaps between contigs which were 'size-unknown' were indicated with a block of 100 N residues. Other N residues in the assemblies indicated gaps of known length, based on read-pair insert size distributions.

Annotation

Identification of predicted CDS (coding segment) regions in the assemblies used a combination of two approaches: ab initio ORF finding using Artemis (<http://www.sanger.ac.uk/science/tools/artemis>) software and transitive annotation using BLAST from known *E. faecium* predicted proteins. A dataset ('EfecDB') comprising all 670,389 *E. faecium* predicted proteins was downloaded from NCBI. For each predicted CDS in each assembly, the EfecDB database was searched using BLASTP. The 'most similar protein' description line was used to assign a protein product to each predicted CDS.

MLST alleles

MLST allele sequences (*atpA*, *ddl*, *gdh*, *purK*, *gyd*, *pstS* and *adk*) for *E. faecium* were downloaded from the PubMLST database (<https://pubmlst.org/efaecium>). These alleles were identified in assembled HTS data from the sequenced strains using blastn and the PubMLST batch sequence query tool. The resulting allelic profiles were used to assign sequence types.

Genome-wide single nucleotide polymorphism analysis

HTS data were used to generate phylogenies based on single nucleotide polymorphism (SNP) analysis, using two different methods. The first method (described by Kaas et al.) was implemented on the Centre for Genomic Epidemiology server (<https://cge.cbs.dtu.dk/services/CSIPhylogeny>) [14]. The second method (described by Bertels et al.) was implemented on the REALPHY server v1.12 (<https://realphy.unibas.ch/fcgi/realphy>) [15].

Specific genes of interest

To identify specific genes of interest in the assemblies, protein sequences were obtained from NCBI (see Appendix 1).

Each sequence was used to search all of the predicted protein sequences in the assemblies using BLASTP, allowing up to 500 hits. The outputs were parsed on the basis of hsp bitscore, a measure of similarity and extent of the similarity region, using a very stringent bitscore threshold of > 250 . All hits were aligned with the query sequence and the resulting multiple sequence alignments were manually inspected using GeneDoc (<http://www.nrbsc.org/old/gfx/genedoc>).

Comparative genomic analysis

Two rounds of analysis were undertaken to identify genes/predicted proteins that were associated with the QD-resistant phenotype. The first round identified predicted proteins in the assemblies that were present or absent from the DO reference genome, using BLASTP with a non-stringent 20% amino acid identity threshold. However, this analysis did not identify predicted proteins that were absent from the DO genome and only present in resistant strains. To address this, a second round of analysis was carried out, with reference to a 'pan genome' constructed using CDS data from all of the sequenced strains. This analysis aimed to identify homologous genes (proteins) that were present only in the assemblies from resistant strains and/or only present in resistant strains with the same MLST sequence type. A BLASTN threshold of 70% nucleotide identity was applied for this analysis.

Results

PCR detection of genes of interest

No PCR products were obtained using published primer sets for *vata*, *vatB*, *vatC*, *vatD*, *vatE*, *vatH*, *vgaA*, *vgaB*, *vgaD*, *vgbA* and *vgbB* on genomic DNA extracted from any of the QD-resistant or QD-susceptible isolates. All of the tested isolates (both QD-resistant and sensitive) were PCR positive using *msrC* and *ermB* primers. For the positive controls, PCR products were seen at the expected band sizes for *S. aureus* ES1767 (*vata*, *vgaA*, *vgbA*), *S. aureus* ES1768 (*vatB*, *vgaB*), *E. faecium* UW1965 (*vatD*) and *E. faecium* UW3540 (*vatE*).

Multi-locus sequence typing (MLST) by HTS

MLST allele sequences (*atpA*, *ddl*, *gdh*, *purK*, *gyd*, *pstS* and *adk*) were identified in assembled HTS datasets for each strain and used to assign MLST sequence types. All seven alleles were identified in all of the sequenced strains, and all strains

had known allelic profiles/sequence types. MLST demonstrated that the two concurrent outbreaks were each dominated by a single clone of QD-resistant *E. faecium*: four QD-resistant isolates were type ST80, of which three were isolated from ward A; three were ST192 and all isolated from ward B. One QD-susceptible isolate of *E. faecium* was also type ST192, with the other three QD-susceptible isolates having different ST types (Table 2).

Genome-wide SNP analysis using two different software pipelines confirmed the strains that were designated as ST80 using MLST formed a single monophyletic cluster and were effectively indistinguishable from each other based on SNPs (Fig. 1).

Comparative genomic analysis

Comparative genomic analysis was performed, comparing the assembled HTS datasets from the QD-resistant isolates (ST80 and ST192 strains), QD-susceptible isolates (all ST types) and the QD-sensitive *E. faecium* DO reference strain. The first comparison was to a list of genes encoding proteins of interest that are known to be associated with QD resistance. All of the sequenced strains contained *ermB*, *msrC* (as expected from the PCR data) and also *lsaE* homologues. However there were no genes (using at least 20% amino acid sequence similarity as a cutoff) belonging to the *vat* (*vatA*, *vatB*, *vatC*, *vatD*, *vatE*, *vatG*) or *vga* (*vgaA*, *vgaB*, *vgaD*) families identified in the QD-resistant or QD-susceptible isolates.

The second comparison was of all predicted protein-coding genes identified in the sequenced strains ($n = 36,664$ in total) to both the DO reference genome ($n = 3114$ genes) and to a ‘pan genome’ of sequences present in at least one of the sequenced strains, but not in the DO reference genome ($n = 4131$ genes). This comparison, using a less stringent cutoff (70% similarity at the DNA level) identified two genetic foci of interest.


First, a total of 68 predicted proteins were identified that were present only in the resistant ST80 strains. Fifty-five of the genes encoding these were located in eight syntenic clusters, corresponding to operons encoding saccharide metabolism, polysaccharide/capsule biosynthesis, or to transposons (identified by the presence of one or more genes annotated as a transposase). None of the 68 predicted proteins were annotated with functions that might confer QD resistance. The comparative analysis did identify a putative multidrug resistance transposon comprised of eight genes located in a single probable transposon in all of the ST80 strains. However, these genes were also present, with six additional flanking genes (HMPREF0351_12793, HMPREF0351_12806) as a transposon in the (QD susceptible) reference genome. Of note, two upstream genes to the transposon in the DO strain encode transcriptional regulators which were absent from the ST80 isolates: HMPREF0351_12795, a hypothetical WYL family

Table 2 Genome assembly summary data for *E. faecium* isolates selected for high-throughput sequencing

Date isolated	Ward	Isolate	QD MIC at baseline	QD phenotype	MLST ST	Read depth	Contigs	Largest contig (bp)	Coverage (bp)	Coding sequences	Not present in DO genome
13/02/2012	A	Ent12	8	R	80	1,961,112	167	113,803	2,978,459	2976	128
20/03/2012	B	Ent8	8	R	192	1,950,000	183	120,337	3,051,329	3071	150
20/06/2012	A	Ent16	8	R	80	1,955,556	171	117,861	2,966,094	2965	125
25/06/2012	A	Ent9	8	R	80	1,961,112	165	109,771	2,955,813	2949	122
11/07/2012	B	Ent13	8	R	192	1,955,556	177	116,441	3,046,475	3048	152
19/07/2012	B	Ent36	8	R	192	1,950,000	176	120,328	2,997,011	2995	134
28/07/2012	B	Ent19	8	R	80	1,955,556	162	133,779	2,973,776	2941	137
02/04/2012	B	Ent22	1	S	192	1,961,112	166	132,639	2,994,545	2984	127
06/04/2012	B	Ent23	1	S	203	1,950,000	201	145,636	3,184,739	3241	170
07/05/2012	A	Ent28	1	S	262	1,961,112	371	189,792	3,192,843	3500	230
01/06/2012	C	Ent31	0.5	S	17	1,944,445	234	117,101	3,056,181	3099	173
20/06/2012	A	Ent34	1	S	78	1,955,556	163	224,457	3,033,536	3027	198

MIC minimum inhibitory concentration (µg/ml), MLST multi-locus sequencing type, QDR quinupristin-dalfopristin resistant, QDS quinupristin-dalfopristin susceptible, S susceptible, I intermediate resistance, R resistant; ward names have been anonymised

Fig. 1 Cladogram depicting the clonal relatedness of Enterococcal isolates studied in this outbreak. S QD-susceptible, R QD-resistant



(S): QD-susceptible; (R): QD-resistant

DNA-binding transcriptional regulator (118 aa) and HMPREF0351_12796, a DNA-binding transcriptional regulator YafY containing HTH and WYL domains (190 aa). A further gene encoding a putative transcriptional repressor protein (HMPREF0351_12805) was present in the DO transposon, but absent from the ST80 assemblies. Analysis of this transposon, which may be de-repressed in the resistant ST80 isolate through the absence of the transcriptional regulators, predicted that it encodes several proteins with possible drug or drug-target modification activities. These include putative kanamycin kinase, streptothricin acetyltransferase, streptomycin aminoglycoside 6-adenyltransferase, SAM-dependent methyltransferase and rRNA (adenine-N(6)-)-methyltransferase enzymes. In addition, the transposon includes an unidentified DNA polymerase domain-containing protein and a small (81aa), unnamed hypothetical protein of unknown function belonging to the DUF1413 superfamily (<http://pfam.xfam.org/family/PF07205>).

The second observation of interest was an additional 56aa leader sequence at the N-terminus of the *lsaE* gene in the ST80 QD-resistant isolates that was not seen in the non-ST80 QD-resistant isolates, the QD-susceptible isolates or the DO reference strain. This gene encodes a homologue for the ATP-binding cassette (ABC) protein that is responsible for QD resistance in *E. faecalis* [16]. A point mutation in this gene (C1349T) has reportedly conferred QD resistance (MIC 4) to *E. faecium* [17]. However, this 56aa leader sequence has been

found in another reference strain, *E. faecium* TX1330, which we confirmed is QD-susceptible.

There were no unique genetic determinants found in the ST192 QD-resistant isolates that were absent from the ST80 QD-resistant isolates, the QD-susceptible isolates and/or the DO reference strain.

Discussion

The potential of high-throughput sequencing is an exciting development in diagnostic bacteriology [18]. To date, the leading application of HTS has been determining clonal relatedness of bacterial isolates in outbreak analysis. However, as antimicrobial resistance is a growing priority in clinical research, HTS has been used to identify novel genes of interest. In enterococcal studies, HTS has already characterised previously unknown genes that confer resistance to linezolid, daptomycin and tigecycline [8–10]. This study sought to identify the novel genetic determinant for QD resistance in our isolates of GRE using HTS and determine the relatedness of two concurrent outbreaks. There are three principal findings from this study, with attendant implications.

First, PCR and HTS analysis confirmed that the QD-resistant *E. faecium* in this outbreak did not encode any known genes that confer high-level resistance to QD. This concurs with the recognition elsewhere that there remain uncharacterised QD

resistance mechanisms among enterococci [6, 7]. Gene targets of interest that were not found using the search strategy employed may have been genuinely absent from the genomes, present in the genome but missing from the assemblies, or not detected due to divergence at the primary sequence level. We consider the latter to be unlikely as two Lsa-family ABC transporter variants that were distinct from—but clearly homologous to—the LsaE query sequence (amino acid sequences were 43% identical and 94% conserved physicochemical properties) were identified using this approach.

On account of the limitations of HTS and assembly strategy, none of the study strains was sequenced to closed genomes so we cannot exclude missing contigs which may harbour resistance determinants.

Currently, QD is not commonly used to treat serious GRE infections, as it has been superseded by agents that are easier to administer and are better tolerated. However, as GRE infections increase in number and acquire further drug resistance, we might expect to see greater dependence on QD in future clinical practice. Rapid resistance screening tests based on currently characterised resistance genes would have failed to detect QD resistance in some of these isolates implicated in this study. This has potential to delay the commencement of appropriate treatment, which could have adverse consequences for patient outcomes in the context of a QD-resistant GRE outbreak.

Second, HTS was useful in demonstrating the multi-clonal nature of this GRE outbreak. The benefit of typing outbreak strains for identifying infection source and transmission routes is well recognised [11, 18]. MLST typing of the HTS data revealed that two clones dominated this outbreak which linked strongly to the ward from which they were isolated: three of four ST80 isolates came from ward A and all four ST192 isolates came from ward B. This alerts infection control practitioners against presuming the association of outbreaks that appear linked in space and time, even if they share atypical features such as unusual antibiograms.

A number of ST80 strains ($n = 17$) from hospitalised patients and/or outbreaks in the UK, Europe, Asia and Africa are listed in the PubMLST *E. faecium* isolates database. The earliest ST80 strain in the database was isolated in Israel in 1997. ST80 is a single-locus variant of the globally disseminated multidrug-resistant ST117 clone and represents a further international hospital-adapted GRE clone [19]. To our knowledge, this is the first study to genomically characterise ST80 strains and to confirm they are circulating in Ireland.

Finally, HTS was of limited usefulness in determining the genetic determinant for QD resistance in this outbreak. After comparative genomic analysis revealed this GRE outbreak was dominated by two distinct clones (ST80 and ST192), it demonstrated that there was no single, consistent genetic determinant for the QD resistance in these isolates. For the ST192 QD-resistant isolates, HTS analysis did not reveal any

significant genetic differences from the QD-susceptible control isolates in the study. However, there were two genetic differences of interest present in the ST80 QD-resistant isolates which were absent in the non-ST80 QD-resistant isolates, the QD-susceptible controls and DO reference strain. These were (i) an additional 56aa leader sequence at the N-terminus of the *lsaE* gene and (ii) a potentially de-repressed transposon encoding five proteins with possible uncharacterised drug-target modification activities plus a hypothetical protein of unknown function.

Leader sequences have been implicated in inducible streptogramin resistance elsewhere. For example, streptogramins bind to the leader sequence ErmBL which stalls ribosome translation and triggers expression of *ermB* which inactivates the antibiotic through methylation [20, 21]. We found the same leader sequence of the *lsaE* gene in another *E. faecium* reference strain (TX1330) which is QD susceptible; however, this is not a truly comparable strain since it does not encode the low-level QD resistance gene *ermB* and is susceptible to glycopeptides [22]. Therefore, the 56aa leader sequence in the *lsaE* gene may possibly combine with the gene products of *ermB* or the depressed transposon of interest to generate the high-level QD resistance seen in the ST80 isolates.

From this study, we conclude that HTS was useful in demonstrating that two concurrent GRE outbreaks, both characterised by unusual QD resistance, were not directly related. It was also helpful in identifying significant genetic differences that offer plausible explanations for QD resistance in some, but not all, of the GRE in this outbreak. We conclude that there are mechanisms of QD resistance in enterococci that are not readily detectable through genomic analysis. This corresponds with the experience of others who have not been successful in using HTS to identify enterococcal mechanisms of linezolid resistance [23]. One possible explanation for this is the presence of resistance determinants that originate beyond the genome. The study of proteomics, for instance, has identified post-translational modifications that can confer antimicrobial resistance that may not be predicted by HTS [24]. As enterococcal resistance increases, QD may form part of our GRE treatment strategy in the future and further work is warranted to characterise QD resistance mechanisms at the post-genomic level.

Acknowledgements The authors are grateful to Prof. Barbara E. Murray (Division of Infectious Diseases, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA) for provision of the DO and TX1330 *Enterococcus faecium* reference strains. Next generation sequencing data was prepared by Alasdair Ivens (SysBioC Ltd., London) and analysed by D.J.F. Preliminary results from this study (prior to high-throughput sequencing) were presented at the 2014 European Congress for Clinical Microbiology and Infectious Diseases in Barcelona, Spain.

Funding This work was supported by a research grant from the Northern Ireland Health and Social Care Research and Development Office (COM/4536/11). The funder had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Compliance with ethical standards

Conflict of interests The authors declare that they have no conflict of interest.

Ethical approval This study did not involve human participants, animals or tissue. All work was undertaken on organisms in accordance with Good Scientific Practice guidelines (Academy of Healthcare Sciences, UK).

Informed consent Not applicable to this study

Appendix 1: QD resistance Genes of Interest

To identify specific QD resistance genes of interest in the assemblies, the following protein sequences were obtained from NCBI:

gi|398085|gb|AAA26683.1|VatA VatA acetyltransferase [*Staphylococcus aureus*]
 gi|1181627|gb|AAA86871.1|VatB VatB [*Staphylococcus aureus*]
 gi|3660657|gb|AAC61671.1|VatC VatC streptogramin A acetyl transferase [*Staphylococcus cohnii*]
 gi|433715|gb|AAA24783.1|VatD VatD SatA streptogramin A acetyltransferase [*Enterococcus faecium*]
 gi|5532424|gb|AAD44719.1|VatE VatE SatG protein [*Enterococcus faecium*]
 gi|261607834|gb|ACX92987.1|VatG VatG streptogramin A acetyltransferase [*Enterococcus faecium*]
 gi|153125|gb|AAA26684.1|VgaA VgaA ATP-binding protein [*Staphylococcus aureus*]
 gi|2769708|gb|AAB95639.1|VgaB VgaB pristinamycin resistance protein VgaB [*Staphylococcus aureus*]
 gi|262340499|gb|ACX92986.2|VgaD VgaD ABC transporter [*Enterococcus faecium*]
 gi|150754|gb|AAA98259.1|VgbA VgbA virginiamycin B hydrolase [Plasmid pIP630]
 gi|3660656|gb|AAC61670.1|VgbB VgbB streptogramin B lactonase [*Staphylococcus cohnii*]
 gi|21492653|gb|AAA27452.2|ErmB ErmB [*Enterococcus faecalis*]
 gi|12659044|gb|AAK01167.1|MsrC MsrC [*Enterococcus faecium*]
 gi|565363052|gb|AHC08069.1|LsaE LsaE [*Enterococcus faecium*]

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

- Arias CA, Murray BE (2012) The rise of the Enterococcus: beyond vancomycin resistance. *Nat Rev Microbiol* 10:266–278
- World Health Organisation (2017) Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1.
- UK Drug Information Pharmacists Group (2000) New medicines on the market: quinupristin-dalfopristin. <http://www.ukmi.nhs.uk/NewMaterial/html/docs/quinupri.pdf>.
- Hollenbeck BL, Rice LB (2012) Intrinsic and acquired resistance mechanisms in Enterococcus. *Virulence* 3:421–433
- Hershberger E, Donabedian S, Konstantinou K, Zervos MJ (2004) Quinupristin-dalfopristin resistance in Gram-positive bacteria: mechanism of resistance and epidemiology. *Clin Infect Dis* 38:92–98
- Jung YH, Shin ES, Kim O, Yoo JS, Lee KM, Yoo JI, Chung GT, Lee YS (2010) Characterization of two newly identified genes, vgaD and vatH, conferring resistance to streptogramin A in *Enterococcus faecium*. *Antimicrob Agents Chemother* 54:4744–4749
- Soltani M, Beighton D, Philpott-Howard J, Woodford N (2001) Identification of vat(E-3), a novel gene encoding resistance to quinupristin-dalfopristin in a strain of *Enterococcus faecium* from a hospital patient in the United Kingdom. *Antimicrob Agents Chemother* 45:645–646
- do Prado GV, Marchi AP, Moreno LZ, Rizek C, Amigo U, Moreno AM, Rossi F, Guimaraes T, Levin AS, Costa SF (2016) Virulence and resistance pattern of a novel sequence type of linezolid-resistant *Enterococcus faecium* identified by whole-genome sequencing. *J Glob Antimicrob Resist* 6:27–31
- Tran TT, Panesso D, Gao H, Roh JH, Munita JM, Reyes J, Diaz L, Lobos EA, Shamoo Y, Mishra NN, Bayer AS, Murray BE, Weinstock GM, Arias CA (2013) Whole-genome analysis of a daptomycin-susceptible enterococcus faecium strain and its daptomycin-resistant variant arising during therapy. *Antimicrob Agents Chemother* 57:261–268
- Cattoir V, Isnard C, Cosquer T, Odhiambo A, Bucquet F, Guérin F, Giard JC (2015) Genomic analysis of reduced susceptibility to tigecycline in *Enterococcus faecium*. *Antimicrob Agents Chemother* 59:239–244
- Raven KE, Gouliouris T, Brodrick H, Coll F, Brown NM, Reynolds R, Reuter S, Török ME, Parkhill J, Peacock SJ (2017) Complex routes of nosocomial vancomycin-resistant *Enterococcus faecium* transmission revealed by genome sequencing. *Clin Infect Dis* 64(7): 886–893
- Soltani M, Beighton D, Philpott-Howard J, Woodford N (2000) Mechanisms of resistance to quinupristin-dalfopristin among isolates of *Enterococcus faecium* from animals, raw meat, and hospital patients in Western Europe. *Antimicrob Agents Chemother* 44(2): 433–436
- Werner G, Hildebrandt B, Witte W (2001) The newly described *msrC* gene is not equally distributed among all isolates of *Enterococcus faecium*. *Antimicrob Agents Chemother* 45(12): 3672–3673
- Kaas RS, Leekitcharoenphon P, Aarestrup FM, Lund O (2014) Solving the problem of comparing whole bacterial genomes across different sequencing platforms. *PLoS One* 9(8):e104984
- Bertels F, Silander OK, Pachkov M, Rainey PB, van Nimwegen E (2014) Automated reconstruction of whole-genome phylogenies from short-sequence reads. *Mol Biol Evol* 31(5):1077–1088
- Singh KV, Weinstock GM, Murray BE (2002) An *Enterococcus faecalis* ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin. *Antimicrob Agents Chemother* 46:1845–1850

17. Isnard C, Malbruny B, Leclercq R, Cattoir V (2013) Genetic basis for in vitro and in vivo resistance to lincosamides, streptogramins A, and pleuromutilins (LSAP phenotype) in *Enterococcus faecium*. *Antimicrob Agents Chemother* 57: 4463–4469
18. Didelot X, Bowden R, Wilson DJ, Peto TE, Crook DW (2012) Transforming clinical microbiology with bacterial genome sequencing. *Nat Rev Genet* 13:601–612
19. Tedim AP, Lanza VF, Manrique M, Pareja E, Ruiz-Garbajosa P, Cantón R, Baquero F, Coque TM, Tobes R (2017) Complete genome sequences of isolates of *Enterococcus faecium* sequence type 117, a globally disseminated multidrug-resistant clone. *Genome Announc* 5(13):e01553–e01516
20. Leclercq R, Courvalin P (1991) Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. *Antimicrob Agents Chemother* 35:1267–1272
21. Arenz S, Ramu H, Gupta P, Berninghausen O, Beckmann R, Vázquez-Laslop N, Mankin AS, Wilson DN (2014) Molecular basis for erythromycin-dependent ribosome stalling during translation of the ErmBL leader peptide. *Nat Commun* 5:3501
22. Qin X, Galloway-Peña JR, Sillanpaa J, Roh JH, Nallapareddy SR, Chowdhury S, Bourgogne A, Choudhury T, Muzny DM, Buhay CJ, Ding Y, Dugan-Rocha S, Liu W, Kovar C, Sodergren E, Highlander S, Petrosino JF, Worley KC, Gibbs RA, Weinstock GM, Murray BE (2012) Complete genome sequence of *Enterococcus faecium* strain TX16 and comparative genomic analysis of *Enterococcus faecium* genomes. *BMC Microbiol* 12:135
23. Chacko K, Pak T, Sebra R, Kasarskis A, Hamula C, Van Bakel H (2016) Longitudinal whole-genome analysis identifies variants associated with vancomycin and linezolid resistance changes in *Enterococcus faecium* in response to treatment. *Abstr Open Forum Infect Dis*, abstr 2001
24. Wang X, He X, Jiang Z, Wang J, Chen X, Liu D, Wang F, Guo Y, Zhao J, Liu F, Huang L, Yuan J (2010) Proteomic analysis of the *Enterococcus faecalis* V583 strain and clinical isolate V309 under vancomycin treatment. *J Proteome Res* 9:1772085